We thank Dr. Xu and colleagues for their comments on our study. They postulate that race might explain differences in findings between the current study and the prior report by Mezquita et al. The main difference inf indings was the association between the lung immune prognostic index (LIPI) and survival outcomes for patients treated with chemotherapy—we identified a significant association whereas Mezquita et al. did not. The study cohort reported by Mezquita et al. was based on patients treated in France and Spain who were likely to be predominantly white. In the pooled clinical trial cohorts of atezolizumab trials, 77% of participants were of white race. As patient cohorts from both studies were predominantly white, race is unlikely to explain differences in results between studies.